Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.54 |
| ▸ | PRCP | P42785 | 7/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9605087 | 0.95 | USP30 (0.59) | USP30PRCPHCRTR1HCRTR2 | |
| SCHEMBL12798598 | 0.90 | USP30 (0.53) | USP30PRCPHCRTR1HCRTR2 | |
| SCHEMBL17192927 | 0.90 | USP30 (0.53) | USP30PRCPHCRTR1HCRTR2 | |
| SCHEMBL12406262 | 0.88 | PRCP (0.47) | USP30PRCPHCRTR1HCRTR2 | |
| SCHEMBL3209122 | 0.87 | USP30 (0.51) | USP30PRCPHCRTR1HCRTR2 | |
| SCHEMBL3226034 | 0.87 | USP30 (0.51) | USP30PRCPHCRTR1HCRTR2 | |
| SCHEMBL9605036 | 0.87 | PRCP (0.53) | USP30PRCPHCRTR1HCRTR2 | |
| SCHEMBL2778341 | 0.86 | PRCP (0.54) | USP30PRCPHCRTR1HCRTR2 | |
| SCHEMBL12404467 | 0.85 | HCRTR1 (0.57) | USP30PRCPHCRTR1HCRTR2 | |
| SCHEMBL9605121 | 0.85 | USP30 (0.49) | USP30PRCPHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2398794-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012018325-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| WO-2010096302-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885PRCP 190/4885HCRTR1 4453/4885 |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885PRCP 190/4885HCRTR1 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.